203 related articles for article (PubMed ID: 12714810)
1. In vitro synergy studies using aztreonam and fluoroquinolone combinations against six species of Gram-negative bacilli.
Critchley IA; Sahm DF; Kelly LJ; Karlowsky JA
Chemotherapy; 2003 May; 49(1-2):44-8. PubMed ID: 12714810
[TBL] [Abstract][Full Text] [Related]
2. Contemporary in vitro synergy rates for aztreonam combined with newer fluoroquinolones and beta-lactams tested against gram-negative bacilli.
Sader HS; Huynh HK; Jones RN
Diagn Microbiol Infect Dis; 2003 Nov; 47(3):547-50. PubMed ID: 14596974
[TBL] [Abstract][Full Text] [Related]
3. In vitro studies of synergistic interaction between aztreonam and cefoperazone.
Borowski J; Zaremba M; Feliński J
Chemioterapia; 1987 Jun; 6(2 Suppl):109-10. PubMed ID: 3151329
[No Abstract] [Full Text] [Related]
4. Pomegranate pericarp extract enhances the antibacterial activity of ciprofloxacin against extended-spectrum β-lactamase (ESBL) and metallo-β-lactamase (MBL) producing Gram-negative bacilli.
Dey D; Debnath S; Hazra S; Ghosh S; Ray R; Hazra B
Food Chem Toxicol; 2012 Dec; 50(12):4302-9. PubMed ID: 22982804
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of aztreonam against gram negative bacteria from clinical specimens and its comparison with other commonly used antibiotics.
Qadri SM; Belobraydic KA
Methods Find Exp Clin Pharmacol; 1986 Apr; 8(4):223-6. PubMed ID: 3088346
[TBL] [Abstract][Full Text] [Related]
6. Synergistic activity profile of an antimicrobial peptide against multidrug-resistant and extensively drug-resistant strains of Gram-negative bacterial pathogens.
Pollini S; Brunetti J; Sennati S; Rossolini GM; Bracci L; Pini A; Falciani C
J Pept Sci; 2017 Apr; 23(4):329-333. PubMed ID: 28176481
[TBL] [Abstract][Full Text] [Related]
7. Cell-wall-inhibiting antibiotic combinations with activity against multidrug-resistant Klebsiella pneumoniae and Escherichia coli.
Hickman RA; Hughes D; Cars T; Malmberg C; Cars O
Clin Microbiol Infect; 2014 Apr; 20(4):O267-73. PubMed ID: 24118201
[TBL] [Abstract][Full Text] [Related]
8. Timed killing kinetic studies of the interaction between ciprofloxacin and beta-lactams against gram-negative bacilli.
Pohlman JK; Knapp CC; Ludwig MD; Washington JA
Diagn Microbiol Infect Dis; 1996 Sep; 26(1):29-33. PubMed ID: 8950526
[TBL] [Abstract][Full Text] [Related]
9. [Quinolone resistance in Gram negative rods in Iceland and association with antibiotic use].
Jónsdóttir K; Kristinsson KG
Laeknabladid; 2008 Apr; 94(4):279-85. PubMed ID: 18460726
[TBL] [Abstract][Full Text] [Related]
10. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1997). I. Susceptibility distribution].
Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Fujime M; Fujita K; Shigeta S; Watanabe J; Igari J; Ogiwara M; Ishibashi K; Oguri T; Yoshida H; Imafuku Y; Yamaguchi K; Matsumoto T; Kashitani F; Murai M; Ooe H; Nishikawa M; Watanabe K; Kobayashi Y; Uchida H; Oka T; Mochida C
Jpn J Antibiot; 1999 Feb; 52(2):93-129. PubMed ID: 10221177
[TBL] [Abstract][Full Text] [Related]
11. In vitro synergy testing of levofloxacin, ofloxacin, and ciprofloxacin in combination with aztreonam, ceftazidime, or piperacillin against Pseudomonas aeruginosa.
Pendland SL; Messick CR; Jung R
Diagn Microbiol Infect Dis; 2002 Jan; 42(1):75-8. PubMed ID: 11821176
[TBL] [Abstract][Full Text] [Related]
12. Combination effect of antibiotics against bacteria isolated from keratitis using fractional inhibitory concentration index.
Suzuki T; Ohashi Y
Cornea; 2013 Jul; 32(7):e156-60. PubMed ID: 23665643
[TBL] [Abstract][Full Text] [Related]
13. In vitro potency of amikacin and comparators against E. coli, K. pneumoniae and P. aeruginosa respiratory and blood isolates.
Sutherland CA; Verastegui JE; Nicolau DP
Ann Clin Microbiol Antimicrob; 2016 Jun; 15(1):39. PubMed ID: 27316973
[TBL] [Abstract][Full Text] [Related]
14. [Susceptibility of clinical isolates to aztreonam].
Nagasawa Z; Nishimura T; Nagumo F; Ueda H; Tadano J; Katoh O; Yamada H
Jpn J Antibiot; 1989 Jun; 42(6):1257-70. PubMed ID: 2507799
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Fosfomycin Resistance Protein FosA by Phosphonoformate (Foscarnet) in Multidrug-Resistant Gram-Negative Pathogens.
Ito R; Tomich AD; McElheny CL; Mettus RT; Sluis-Cremer N; Doi Y
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993329
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of azithromycin in combination with amikacin, ceftazidime, ciprofloxacin or imipenem against clinical isolates of Acinobacter baumannii.
Fernández-Cuenca F; Martínez-Martínez L; Pascual A; Perea EJ
Chemotherapy; 2003 May; 49(1-2):24-6. PubMed ID: 12714805
[TBL] [Abstract][Full Text] [Related]
17. [Susceptibility of clinical bacterial isolates to aztreonam].
Murase M; Niiya T; Takeuchi N
Jpn J Antibiot; 1987 Sep; 40(9):1698-706. PubMed ID: 3121888
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of flouroquinolone therapy for gram-negative infections within the intensive care unit setting.
Hassoun A; Eiland E
Am J Med; 2006 Jun; 119(6):e7. PubMed ID: 16750952
[No Abstract] [Full Text] [Related]
19. Restoring the activity of the antibiotic aztreonam using the polyphenol epigallocatechin gallate (EGCG) against multidrug-resistant clinical isolates of
Betts JW; Hornsey M; Higgins PG; Lucassen K; Wille J; Salguero FJ; Seifert H; La Ragione RM
J Med Microbiol; 2019 Oct; 68(10):1552-1559. PubMed ID: 31419210
[No Abstract] [Full Text] [Related]
20. Bactericidal activity of ertapenem against major intra-abdominal pathogens.
Borbone S; Cascone C; Santagati M; Mezzatesta ML; Stefani S
Int J Antimicrob Agents; 2006 Nov; 28(5):396-401. PubMed ID: 17045463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
